Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
Authors' conclusion
Tirzepatide was associated with statistically significantly greater weight and waist circumference reduction versus oral semaglutide and improved or similar cardiometabolic benefits and safety.
Study context
- Population
- Adults without T2D with obesity (BMI ≥ 30 kg/m²), or overweight (BMI ≥ 27 kg/m²) with ≥ 1 obesity-related complication2 pivotal trials
- Comparison
- Weekly injectable tirzepatide 5, 10 and 15 mg vs daily oral semaglutide 50 mg
- Outcome
- Weight reduction
Methodological detailsMultilevel network meta-regression (ML-NMR), adjusted for differences in sex, ethnicity and outcome baselines
- ML-NMR
- Adjusted for differences in sex, ethnicity and outcome baselines
Main finding
As reported in the abstract
Each group vs oral semaglutideMean difference, % (CI)
Tirzepatide 10 mg
−4.48(−6.35 to −2.61)
Tirzepatide 15 mg
−5.59(−7.52 to −3.77)
Further findings
| Outcome | Mean difference (cm) (CI) | |
|---|---|---|
| Waist circumferenceTirzepatide 10 mgvs Oral semaglutide | −3.60 (−5.59 to −1.72) | |
| Waist circumferenceTirzepatide 15 mgvs Oral semaglutide | −4.32 (−6.30 to −2.40) | |
| −10−505Difference, cm (linear scale) |
Achieving ≥ 5%/10%/15%/20% weight reduction
- Tirzepatide 10 and 15 mg: higher odds vs oral semaglutide
Cardiometabolic benefits
- Improved or generally comparable for tirzepatide vs oral semaglutide
Original publication
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity. Diabetes Obes Metab. Published 28 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →